

Supplementary Table 2. Treatments and clinical outcomes of the study patients (n=1,005)

	All	Non-severe (n=872, 86.8%)	Severe (n=133, 13.2%)	P-value*
Treatment				
Antiviral therapy	584/1,005 (58.1)	464/872 (53.2)	120/133 (90.2)	<0.001
Lopinavir/ritonavir	563/1,005 (56.0)	452/872 (51.8)	111/133 (83.5)	<0.001
Darunavir/cobicistat	51/1,005 (5.1)	18/872 (2.1)	33/133 (24.8)	<0.001
Hydroxychloroquine	537/1,005 (53.4)	438/872 (50.2)	99/133 (74.4)	<0.001
Systemic glucocorticoid	168/1,005 (16.7)	61/872 (7.0)	107/133 (80.5)	<0.001
Immunoglobulin	26/1,005 (2.6)	3/872 (0.3)	23/133 (17.3)	<0.001
Oxygen support				
Nasal cannula or venturi mask	162/1,005(16.1)	142/872 (16.3)	20/133 (15.0)	0.716
High-flow nasal cannula	57/1,005 (5.7)	14/872 (1.6)	43/133 (32.3)	<0.001
Invasive mechanical ventilation	70/1,005 (7.0)	0/872 (0.0)	70/133 (52.6)	<0.001
Invasive mechanical ventilation and ECMO	18/1,005 (1.8)	0/872 (0.0)	18/133 (13.5)	<0.001
Complication				
ICU admission	97/1,005 (9.7)	14/872 (1.6)	83/133 (62.4)	<0.001
Septic shock	80/1,005 (8.0)	10/872 (1.1)	70/133 (52.6)	<0.001
Acute respiratory distress syndrome	113/1005 (11.2)	0/872 (0.0)	113/133 (85.0)	<0.001
Acute kidney injury	55/1,005 (5.5)	9/872 (1.0)	46/133 (34.6)	<0.001
Continuous renal-replacement therapy	22/1,005 (2.2)	1/872 (0.1)	21/133 (15.8)	<0.001
Secondary infection	41/1,005 (4.1)	24/872 (2.8)	17/133 (12.8)	<0.001
Clinical outcome				
Death	77/1,005 (7.7)	8/872 (0.9)	69/133 (51.9)	<0.001
Discharge	816/1,005 (81.2)	778/872 (89.2)	38/133 (28.6)	<0.001
Transfer	52/1,005 (5.2)	45/872 (5.2)	7/133 (5.3)	
Hospitalization	60/1,005 (6.0)	41/872 (4.7)	19/133 (14.3)	
Hospital stay (days)	22 (15–31)	22 (16–31)	22 (9–40)	0.602

Values are expressed as median (interquartile range) or numbers (%).

ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.

*Calculated by Student's *t* test (or the Mann-Whitney *U* test, if appropriate) and chi-squared test (or Fisher's exact test, if appropriate).